Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2/3 Completed 148 enrolled Transgene

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.

Timeline

Start: 2005-12
Primary completion: 2010-03
Completion: 2010-03

Publications

Results Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011 Nov;12(12):1125-33. doi: 10.1016/S1470-2045(11)70259-5. Epub 2011 Oct 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA-MUC1-IL2	Vaccine	1e+08 unknown	Subcutaneous
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	1250 mg/m2	Intravenous

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications